Quick Answer
4D Molecular Therapeutics, Inc. reported Diluted EPS of $2.42 per share (loss) for fiscal year 2025.
4D Molecular Therapeutics, Inc. Diluted EPS — Annual History
| Fiscal Year | Diluted EPS | YoY Change |
|---|---|---|
| 2025 | -$2.42 | +18.8% |
| 2024 | -$2.98 | -15.5% |
| 2023 | -$2.58 | +22.3% |
| 2022 | -$3.32 | -29.2% |
| 2021 | -$2.57 | — |
Quarterly Diluted EPS
| Quarter Ending | Diluted EPS | YoY | QoQ |
|---|---|---|---|
| September 30, 2025 | -$1.01 | -27.8% | -3.1% |
| June 30, 2025 | -$0.98 | -55.6% | -14.0% |
| March 31, 2025 | -$0.86 | -30.3% | -8.9% |
| September 30, 2024 | -$0.79 | -229.2% | -25.4% |
| June 30, 2024 | -$0.63 | +18.2% | +4.5% |
| March 31, 2024 | -$0.66 | +25.0% | -175.0% |
| September 30, 2023 | -$0.24 | +69.6% | +68.8% |
| June 30, 2023 | -$0.77 | +11.5% | +12.5% |
- 4D Molecular Therapeutics, Inc. showed an increase of +18.8% in Diluted EPS compared to the prior fiscal year.
- Over the 2021–2025 period, 4D Molecular Therapeutics, Inc.’s diluted eps has grown by 5.8% (from $2.57 per share (loss) to $2.42 per share (loss)).
- The most recent figure is from 4D Molecular Therapeutics, Inc.’s fiscal year 2025 report (Form 10-K), filed with the SEC on March 18, 2026.
- All figures are sourced from SEC EDGAR XBRL filings, last verified June 17, 2026.
Last verified: